Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II

W. Sybesma, C. Rohde, P. Bardy, JP. Pirnay, I. Cooper, J. Caplin, N. Chanishvili, A. Coffey, D. De Vos, AH. Scholz, S. McCallin, HM. Püschner, R. Pantucek, R. Aminov, J. Doškař, Dİ. Kurtbӧke,

. 2018 ; 7 (2) : . [pub] 20180423

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024085

This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024085
003      
CZ-PrNML
005      
20190517232623.0
007      
ta
008      
180709s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics7020035 $2 doi
035    __
$a (PubMed)29690620
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
245    00
$a Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II / $c W. Sybesma, C. Rohde, P. Bardy, JP. Pirnay, I. Cooper, J. Caplin, N. Chanishvili, A. Coffey, D. De Vos, AH. Scholz, S. McCallin, HM. Püschner, R. Pantucek, R. Aminov, J. Doškař, Dİ. Kurtbӧke,
520    9_
$a This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sybesma, Wilbert $u Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, CH-8008 Zürich, Switzerland. wilbert.sybesma@gmail.com. Nestlé Research Center, Nestec Ltd., Vers-chez-les-Blanc, CH-1000 Lausanne, Switzerland. wilbert.sybesma@gmail.com.
700    1_
$a Rohde, Christine $u Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, Germany. chr@dsmz.de.
700    1_
$a Bardy, Pavol $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech Republic. bardy.pavol@mail.muni.cz.
700    1_
$a Pirnay, Jean-Paul $u Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, B-1120 Brussels, Belgium. jean-paul.pirnay@telenet.be.
700    1_
$a Cooper, Ian $u School of Pharmacy and Biomolecular Sciences and School of Environment & Technology, University of Brighton, Brighton BN2 4GJ, UK. I.Cooper@brighton.ac.uk.
700    1_
$a Caplin, Jonathan $u School of Pharmacy and Biomolecular Sciences and School of Environment & Technology, University of Brighton, Brighton BN2 4GJ, UK. J.L.Caplin@brighton.ac.uk.
700    1_
$a Chanishvili, Nina $u Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia. nina.chanishvili@gmail.com.
700    1_
$a Coffey, Aidan $u Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, UK. aidan.coffey@cit.ie.
700    1_
$a De Vos, Daniel $u Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, B-1120 Brussels, Belgium. daniel_de_vos@skynet.be.
700    1_
$a Scholz, Amber Hartman $u Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, Germany. Amber.H.Scholz@dsmz.de.
700    1_
$a McCallin, Shawna $u Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland. shawna.mccallin@unil.ch.
700    1_
$a Püschner, Hilke Marie $u Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, Germany. Hilke.Pueschner@dsmz.de.
700    1_
$a Pantucek, Roman $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech Republic. pantucek@sci.muni.cz.
700    1_
$a Aminov, Rustam $u School of Medicine & Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, UK. rustam.aminov@gmail.com.
700    1_
$a Doškař, Jiří $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech Republic. doskar@sci.muni.cz.
700    1_
$a Kurtbӧke, D İpek $u GeneCology Research Centre and the Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia. ikurtbok@usc.edu.au.
773    0_
$w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 7, č. 2 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29690620 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20190517232720 $b ABA008
999    __
$a ind $b bmc $g 1316072 $s 1021003
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 7 $c 2 $e 20180423 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace